Familial hypertrophic cardiomyopathy: Cornering the rat

Cardiovascular Research

Volumn 47, Issue 2, 2000, Pages 210-211

  Kowey, Peter R ^a,b   Yan, Gan Xin ^a,b   Xu, Xiaoping ^a,b  

^a LANKENAU HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ARRHYTHMOGENESIS; CLINICAL FEATURE; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SHORT SURVEY;

ACTION POTENTIALS; ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DISEASE MODELS, ANIMAL; HUMANS; PROGNOSIS; RATS; RESEARCH;

EID: 0033899501     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00134-6     Document Type: Short Survey

References (10)

1. Spirito P., Seidman C.E., McKenna W.J., Maron B.J. The management of hypertrophic cardiomyopathy. New Engl J Med. 336:1997;775-785.
2. Aronson R.S. Mechanisms of arrhythmia in ventricular hypertrophy. J Cardiovasc Electrophysiol. 2:1991;249-261.
3. Kowey P.R., Friehling T.D., Sewter J., Wu Y., Sokil A., Paul J., Nocella J. Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation. 83:1991;2067-2075.
4. Jurkiewicz N.K., Wang J., Fermini B., Sanguinetti M.C., Salata J.J. Mechanism of action potential prolongation RP 58866 and its active enantiomer, tertikalant. Block of the rapidly activating delayed rectifier potassium current. Circulation. 94:1996;2938-2946.
5. Rials S.J., Wu Y., Liu T., Xu X., Bharucha D.B., Marinchak R.A., Kowey P.R. Left ventricular hypertrophy increases vulnerability to bradycardia and D-sotalol induced early afterdepolarizations (abstract). J Am Coll Cardiol. 31:1998;252A.
6. Maron B.J., Shen W.K., Link M.S., Epstein A.E., Almquist A.K., Daubert J.P., Bardy G.H., Favale S., Rea R.F., Boriani G., Estes M., Spirito P. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. New Engl J Med. 342:2000;365-373.
7. Watkins H. Sudden death in hypertrophic cardiomyopathy (editorial). New Engl J Med. 342:2000;422-423.
8. Frey N., Franz W.M., Gloeckner K., et al. Transgenic rat hearts expressing a human cardiac troponin T deletion reveal diastolic dysfunction and ventricular arrhythmias. Cardiovasc Res. 47:2000;254-264.
9. Rials S.J., Wu Y., Xu X., Filart R.A., Marinchag R.A., Kowey P.R. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation. 96:1997;1330-1336.
10. Bonne G., Carrier L., Richard P., Hainque B., Schwartz K. Familial hypertrophic cardiomyopathy: from mutation to functional defects. Circ Res. 83:1998;580-593.